FMP
NewAmsterdam Pharma Company N.V.
NAMS
NASDAQ
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
20.03 USD
0.9 (4.49%)
Historical Prices
From:
To:
About
ceo
Dr. Michael Harvey Davidson FACC, Facp., M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
CIK
0001936258
ISIN
NL00150012L7
CUSIP
N/A
Address
Gooimeer 2-35
Phone
31 35 206 2971
Country
NL
Employee
68
IPO Date
Feb 9, 2021
Financial Statement
Earnings
NAMS Financial Summary
CIK
0001936258
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
NL00150012L7
Country
NL
Price
20.03
Beta
-0
Volume Avg.
967.12k
Market Cap
2.25B
Shares
-
52-Week
14.06-27.29
DCF
8.43
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-7.82
P/B
-
Website
https://www.newamsterdampharma.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NAMS News
Alex Lavoie
Dec 15, 2024
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Investment In...
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cardiovascular diseases. As a company in the early stages of development, NAMS invests heavily in research and development (R&D) to bring its innovative treatments to market. This investment strategy is common among its peers in the biopharmaceutical industry. NAMS currently has a Return on Invested Capital (ROIC) of -44.65% and a Weighted Average Cost ...
Danny Green
Nov 25, 2024
NewAmsterdam Pharma Company N.V. Faces Capital Efficiency Ch...
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage pharmaceutical company focused on developing transformative therapies for cardiovascular diseases. The company is currently facing challenges in capital efficiency, as indicated by its financial metrics. In the competitive landscape, NewAmsterdam Pharma's peers include companies like ProKidney Corp., Nuvalent, Inc., PepGen Inc., Tyra Biosciences, Inc., and HilleVax, Inc. NewAmsterdam Pharma's Return on Invested Capital (ROIC) is...
GlobeNewsWire
Jul 26, 2024
NewAmsterdam Pharma to Announce Topline Data from Pivotal Ph...
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will report topline data from the Company's Ph...
Seeking Alpha
Jul 5, 2024
NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalys...
NewAmsterdam Pharma Company N.V. expects data from the BROOKLYN study, using obicetrapib for the treatment of patients with HeFH, in Q3 of 2024. Data from the BROADWAY study, using obicetrapib for the treatment of patients with ASCVD, expected Q4 of 2024. Data from the TANDEM study, using obicetrapib + ezetimibe for the treatment of patients with HeFH and/or ASCVD, expected Q1 of 2025.
GlobeNewsWire
Mar 25, 2024
NewAmsterdam Pharma to Present New Analysis from the Phase 2...
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional data from the Ph...
Zacks Investment Research
Mar 13, 2024
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.
GlobeNewsWire
Feb 1, 2024
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talk...
NAARDEN, the Netherlands and MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of N...
Seeking Alpha
Oct 2, 2023
NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakt...
New clinical data shows the potential of obicetrapib in treating early Alzheimer's disease in patients with the ApoE4 mutation. The Phase IIa trial demonstrated positive biomarker indications and good safety profiles for obicetrapib. NewAmsterdam Pharma's venture into Alzheimer's research could be an undervalued growth avenue, but there are risks and the investment balance between cardiovascular studies and Alzheimer's research is crucial.
